BE2012 | REV-ERBα/ß antagonist

CAS:
 667889-47-6
Catalog Number:
 10-4417
BE2012 chemical structure

Available Options

Size:PriceQuantity 
5 mg$90.00
25 mg$340.00
Request Quote / Bulk / Custom Size
Product Inquiry

BE2012 (667889-47-6) is an antagonist of REV-ERBα (EC50 = 285 nM) and REV-ERBß (EC50 = 346 nM).  Highly selective with no activity against a panel of nine closely related nuclear receptors and other receptors.  BE2012 induced myogenesis in a mouse model of acute muscle injury resulting in muscle regeneration and repair via induction of transcription factors Myf5 and Myod.

References/Citations:

  1. Maram et al. (2026) Discovery of BE2012, a First-in-Class REV-ERBα/ß Antagonist with Favorable Selectivity and Pharmacokinetics, and In Vivo Efficacy in Inducing Key Myogenic Factors for Muscle Repair upon Acute Muscle Injury; J.  Med. Chem. 69 439
667889-47-6, BE2012, BE2012 supplier, REV ERB antagonist, REV ERBß antagonist, REV ERBα antagonist, REV ERBα/ß antagonist
CAS:
667889-47-6
Catalog Number:
10-4417
Activity:
REV ERBα/ß antagonist
Chemical Names:
3-Amino-2-(-4-tert-butyl)phenyl)quinazolin-4(3H)-one
Molecular Weight:
293.37
Molecular Formula:

C18H19N3O

Solubility:
Soluble in DMSO (45 mg/ml)
Physical Properties:
White solid
Purity:

>98% HPLC
NMR: (Conforms)

Storage Temperature:
-20°C
Stability:
Stable for up to 1 year when stored as supplied @ -20°C. Solutions in DMSO may be stored at -20°C for up to 3 months.
Shipping Code:
RT

Safety Data Sheet:

Download Safety Data Sheet

Product Data Sheet:

Download Product Data Sheet

Materials provided by Focus Biomolecules are for laboratory research use only and are not intended for human or veterinary applications. Please note that we do not sell to individuals and that all orders placed by non-research organizations will incur a $20 restocking/refund fee

BE2012 (667889-47-6) is an antagonist of REV-ERBα (EC50 = 285 nM) and REV-ERBß (EC50 = 346 nM).  Highly selective with no activity against a panel of nine closely related nuclear receptors and other receptors.  BE2012 induced myogenesis in a mouse model of acute muscle injury resulting in muscle regeneration and repair via induction of transcription factors Myf5 and Myod.

References/Citations:

  1. Maram et al. (2026) Discovery of BE2012, a First-in-Class REV-ERBα/ß Antagonist with Favorable Selectivity and Pharmacokinetics, and In Vivo Efficacy in Inducing Key Myogenic Factors for Muscle Repair upon Acute Muscle Injury; J.  Med. Chem. 69 439